VTRO (Vitro Biopharma) EBIT per Share: $-0.06 (TTM As of Oct. 2022)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Vitro Biopharma EBIT per Share?

Vitro Biopharma VTRO EBIT per Share is $-0.06 as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's EBIT per Share for the three months ended in Oct. 2022 was $-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2022 was $-0.06.

During the past 3 years, the average EBIT per Share Growth Rate was -214.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -117.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was -21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Vitro Biopharma's EBIT per Share or its related term are showing as below:

VTRO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -214.1 Med: 9.55 Max: 32.7
Current: -214.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Vitro Biopharma was 32.70% per year. The lowest was -214.10% per year. And the median was 9.55% per year.

VTRO's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 15.5 vs VTRO: -214.10

Vitro Biopharma's EBIT for the three months ended in Oct. 2022 was $-6.66 Mil.

Vitro Biopharma (AMEX:VTRO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Vitro Biopharma EBIT per Share Related Terms

Vitro Biopharma EBIT per Share Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma EBIT per Share Chart

Vitro Biopharma Annual Data

Trend

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

Oct17

Oct21

Oct22

EBIT per Share

Get a 7-Day Free Trial

-0.01

-0.02

-0.08

-0.06

Vitro Biopharma Quarterly Data
	Oct00	Oct01	Oct02	Oct03	Oct04	Oct05	Oct06	Oct07	Oct08	Oct09	Oct10	Oct11	Oct12	Oct13	Oct14	Oct15	Oct17	Oct21	Oct22
EBIT per Share	Get a 7-Day Free Trial														-0.01	-0.01	-0.02	-0.08	-0.06

Vitro Biopharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Vitro Biopharma's EBIT per Share for the fiscal year that ended in Oct. 2022 is calculated as

	EBIT per Share		(A: Oct. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.662	/	107.725
=	-0.06

Vitro Biopharma's EBIT per Share for the quarter that ended in Oct. 2022 is calculated as

	EBIT per Share		(Q: Oct. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.662	/	107.725
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of $-0.06 mean?

Vitro Biopharma (VTRO) has a EBIT per Share of $-0.06 as of Oct. 2022. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vitro Biopharma and its competitors.

Is Vitro Biopharma's EBIT per Share too high?

Vitro Biopharma's current EBIT per Share is $-0.06.

How does Vitro Biopharma's EBIT per Share compare to ?

Vitro Biopharma's EBIT per Share of $-0.06 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Biotechnology company?

The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vitro Biopharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitro Biopharma's current EBIT per Share is $-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vitro Biopharma stock overvalued right now?

Vitro Biopharma (VTRO) has a current EBIT per Share of $-0.06. The current EBIT per Share is $-0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current EBIT per Share is $-0.06 as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies

Address 4621 Technology Drive, Golden, CO, USA, 80403

Website http://www.vitrobiopharma.com

Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.